Liquidia’s Shareholder Call Highlights YUTREPIA Progress but No Material Shift in Risk Profile

What happened

Liquidia held a shareholder/analyst call following its Q3 2025 results, which showed YUTREPIA product sales of $51.7 million and over 2,000 prescriptions. The company reiterated its commercial momentum but offered no significant updates on the ongoing United Therapeutics litigation or financing covenants. The master report continues to flag substantial doubt about going concern and notes the stock’s 221% run-up already prices in optimistic assumptions. The call did not alter the high-risk binary nature of the investment case.

Implication

Near-term price action will hinge on prescription growth and any court rulings. Investors should remain cautious given the lack of margin of safety, expensive debt covenants, and still negative free cash flow. Any slowdown in YUTREPIA uptake or adverse legal developments could trigger sharp downside.

Thesis delta

The call offered no new information; the thesis remains unchanged. Continue to view LQDA as a high-conviction binary bet where the current price embeds favorable outcomes that are far from assured.